Article
PharmTech Multimedia
Dennis Brandl, President, at BR&L Consulting, spoke with Pharmaceutical Technology about what should be expected when transitioning from paper to EBR.
Dennis Brandl, President, at BR&L Consulting, spoke with Pharmaceutical Technology about what should be expected when transitioning from paper to EBR.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.